Compare BioNano Genomics Inc (BNGO) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Procter & Gamble Co — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Procter & Gamble Co trades at $146.11 (market cap $340.16B). The key difference: Procter & Gamble Co is far larger — about 25769.7× BioNano Genomics Inc's market cap, and Procter & Gamble Co pays a 2.92% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | PG | |
|---|---|---|
Market Cap | $13.20M | $340.16B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $167.18 |
52-Week Low | $1.09 | $138.10 |
Enterprise Value | $15.81M | $365.64B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Procter & Gamble (PG) trades at $148.37, up 0.9% on the day, with a neutral technical signal and bullish moving averages. The stock shows stable revenue near $84.3 billion in 2025 and consistent earnings beats, with a net income margin of 19.16%. Recent news highlights its dividend reliability amid market volatility, while analyst consensus leans bullish with a $161.71 price target.
PG offers steady growth and income appeal, supported by strong cash flow and a 69-year dividend growth streak. Risks include premium valuation multiples and soft demand concerns. Upside depends on execution of supply chain efficiencies and sustained margin strength in a competitive consumer staples landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
